Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 1.7B 1.54B 1.42B 1.28B 2.42B 158B 2.51B 17.13B 6.78B 85.48B 6.36B 6.23B 270B P/E 2026 *
-3.06x
P/E 2027 * -3.28x
Enterprise Value 1.18B 1.07B 990M 893M 1.69B 110B 1.75B 11.93B 4.72B 59.5B 4.43B 4.33B 188B EV / Sales 2026 *
29.1x
EV / Sales 2027 * 31.2x
Free-Float
97.47%
Yield 2026 *
-
Yield 2027 * -
1 day+8.27%
1 week-16.30%
Current month-25.43%
1 month-16.76%
3 months-2.75%
6 months+3.98%
Current year-26.53%
1 week 2.5
Extreme 2.5
3.46
1 month 2.5
Extreme 2.5
4.52
Current year 2.5
Extreme 2.5
5.24
1 year 2.5
Extreme 2.5
5.24
3 years 2.5
Extreme 2.5
15.74
5 years 2.5
Extreme 2.5
21.19
10 years 2.5
Extreme 2.5
42.81
Manager TitleAgeSince
Chief Executive Officer 43 2025-12-31
Director of Finance/CFO 48 2024-11-19
Chief Tech/Sci/R&D Officer 57 2026-04-05
Director TitleAgeSince
Director/Board Member 44 2013-11-03
Director/Board Member 62 2013-11-03
Director/Board Member 37 2016-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/3/26 Sell

Founder

-40,000 0.0067%
11/2/26 Free

Chairman

156,658 0.0262%
10/6/26 Sell

Founder

-50,000 0.0093%
Change 5-day change 1-year change 3-year change Capi.($)
+8.27%-16.30%-27.76%-56.20% 1.7B
-1.34%-4.12%+53.70%+68.83% 66.37B
+1.50%-0.94%+9.97%+92.41% 58.86B
+0.81%+0.87%+26.49%+87.40% 55.22B
-1.88%-3.24%+11.66%+116.29% 47.21B
-0.44%-5.64%+19.23%+26.19% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.37%-10.35%+129.53%+645.51% 35.19B
+0.29%-1.38%+83.30%+58.20% 32.66B
-1.01%+0.70%-39.69%+393.89% 26.73B
Average +0.20%-5.05%+28.12%+147.38% 40B
Weighted average by Cap. -0.54%-3.01%+33.98%+143.96%

Financials

2026 *2027 *
Net sales 40.57M 36.83M 34.02M 30.69M 57.94M 3.79B 60.15M 410M 162M 2.05B 152M 149M 6.46B 44.31M 40.22M 37.16M 33.52M 63.28M 4.14B 65.71M 448M 177M 2.23B 166M 163M 7.06B
Net income -479M -434M -401M -362M -684M -44.72B -710M -4.84B -1.91B -24.13B -1.8B -1.76B -76.24B -480M -436M -403M -364M -686M -44.89B -713M -4.86B -1.92B -24.23B -1.8B -1.76B -76.54B
Net Debt -515M -468M -432M -390M -736M -48.15B -764M -5.21B -2.06B -25.98B -1.93B -1.89B -82.08B -312M -284M -262M -236M -446M -29.19B -463M -3.16B -1.25B -15.75B -1.17B -1.15B -49.76B
Projected Income Statement - Annual - Recursion Pharmaceuticals, Inc.
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
26-11-18 US$2.989 +9.88% 6,011,725
26-11-17 US$2.720 -6.37% 41,021,204
26-11-16 US$2.905 -8.79% 19,788,026
26-11-13 US$3.185 -4.35% 16,719,541
26-11-12 US$3.330 -7.24% 20,569,041
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Recursion Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.720USD
Average target price
6.767USD
Spread / Average Target
+148.77%
  1. Stock Market
  2. Stocks
  3. RXRX Stock